Andrea Laimbacher

This study identifies molecular changes in right ventricular tissue from DCM patients, showing that pulmonary pressure load drives transcriptional remodelling and fibrosis, while proteomic changes reflect immune activation and metabolic shifts.

This study identifies dysferlin as an antifibrotic regulator that limits fibroblast differentiation and myocardial fibrosis in heart failure.

This study shows lanifibranor reduces TGF-β1-induced cardiac fibrosis and improves cardiomyocyte function in human models.

This paper shows that elafibranor reduces TGF-β1-induced cardiac fibrosis by improving redox-metabolic and bioenergetic processes in human cardiac models.

This study compares two culture systems for mouse living myocardial slices, finding the biomimetic system provides better viability, structure, and function for cardiac fibrosis research.

This study characterizes PDE4B expression in systemic sclerosis (SSc) tissues, showing dysregulation in immune cells and protein enrichment in activated fibroblasts, supporting PDE4B as a therapeutic target.

This study identifies disease-specific fibroblast-myeloid interactions in RA synovium, showing SPP1 signaling and fibroblast-myeloid-dendritic interactions drive RA inflammation by linking innate immunity to autoimmunity.